2026 SPS Seattle | HER’s First – Zongertinib’s Push to First-Line Setting in HER2 Positive Non-Small Cell Lung Cancer
0% Complete
Course Content
This material is non-CME, no credits are available, and a certificate will not be provided upon completion.
Course Details
- Duration
- 0.00 hour
- Released
- Oct 26, 2026
- Last Review
- Oct 26, 2026
- Expires
- Oct 26, 2029
Target Audience
Pharmacists
Pharmacy Technicians
Accreditation
N/A
